Keytruda/chemo combo extends survival in NSCLC patients

17th January 2018 Uncategorised 0

A combination of MSD’s Keytruda and chemotherapy extended overall survival when used as a first-line treatment of patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).

More: Keytruda/chemo combo extends survival in NSCLC patients
Source: News